Advanced Filters
noise

Dementia Clinical Trials

A listing of Dementia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 807 clinical trials
D Daniela Sacchetti, MS

Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia

While many have strongly suggested that transcranial direct current stimulation (tDCS) may represent a beneficial intervention for patients with primary progressive aphasia (PPA), this promising technology has not yet been applied widely in clinical settings. This treatment gap is underscored by the absence of any neurally-focused standard-of-care treatments to mitigate …

50 - 90 years of age All Phase 2
S Sarah M Boland, CCRP

The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech

The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing.

18 years of age All Phase N/A
A Arvid Rongve, Phd

Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial

This is a confirmatory investigational medicinal product (IMP) study to investigate the effects on cognition, functional decline and on neuropsychiatric symptoms of the Glucocerebrosidase (GCase) enhancing chaperone ambroxol in participants diagnosed with prodromal and early dementia with Lewybodies (DLB).

50 - 85 years of age All Phase 2
C Carolyn Paiz, BS

Comparing Antipsychotic Medications in LBD Over Time

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to …

years of age All Phase 4

Safety and Efficacy of AR1005 in Patients with Lewy Body Disease

This study is a phase 2a, single-center, double-blind and randomized clinical trial that evaluates the safety and efficacy of AR1005 administration in 60 patients with cognitive impairment due to Lewy body disease. The study evaluates whether the administration of AR1005 in patients with cognitive impairment due to Lewy body disease …

60 years of age All Phase 2

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half …

55 - 85 years of age All Phase 2
C Claire Harrison Harrison, MD

Cognitive Screening Made Easy for PCPs - Administrative Supplement

This project will facilitate early detection of cognitive decline in older adults through development and implementation of an automated risk assessment and cognitive screening tool for use in primary care. By providing an automated tool developed specifically to address the needs of PCPs, it will be easier to screen for …

60 years of age All Phase N/A
S Stephanie A Ballard, MSc

The Pain Reduction Using Immersive Virtual Reality During Wound Care Evaluation Study at Maimonides (PRISM) - Pilot Study

This study will test whether immersive virtual reality (iVR) can reduce pain and discomfort during wound care for residents living in long-term care (LTC). Pressure ulcers are common and painful among older adults, and dressing changes often cause additional distress. Up to 20 residents at the Donald Berman Maimonides Geriatric …

years of age All Phase N/A
F Fatima Jebahi, MS

Enhancing Language Function in Aphasia

Aphasia is an acquired impairment of language, that commonly results from damage to language areas in the brain (typically the left side of the brain). This impairment is seen in many aspects of language, including understanding, speaking, reading and writing. It is estimated that about 2 million individuals are currently …

21 - 80 years of age All Phase N/A
A Arianna Ciullini, PHD

Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches

Diagnosis of ALS/FTD disease spectrum is challenging because it largely relies on clinical symptoms. Identifying novel biomarkers is essential for a paradigm shift towards a more precise biological-based diagnosis. To achieve this aim, having access to proper specimens and analytical methods is crucial. Our team of experts in neurology, biology, …

18 years of age All Phase N/A

Simplify language using AI